使用β受体阻滞剂与接受膝关节置换术的风险:一项巢式病例对照研究
该巢式病例对照研究纳入2010至2019年新发膝痛患者600例,比较2018至2019年行初次全膝关节置换术者与未行手术者。随访期间任何β受体阻滞剂使用与全膝关节置换术可能性降低相关(调整OR 0.51;95%CI 0.34-0.77),非选择性β1受体阻滞剂及长期使用亦与更低可能性相关。
要点
- 随访期间任何β受体阻滞剂使用与全膝关节置换术可能性降低相关(调整OR 0.51;95%CI 0.34-0.77)。
- 非选择性β1受体阻滞剂调整OR 0.42(95%CI 0.24-0.70),选择性β1受体阻滞剂调整OR 0.69(95%CI 0.36-1.31)。
- 使用≥5年者调整OR 0.36(95%CI 0.22-0.60),使用<1年者调整OR 0.41(95%CI 0.20-0.85)。
核心结论
- 使用非选择性β受体阻滞剂与接受全膝关节置换术的可能性降低相关,长期治疗者接受全膝关节置换术的可能性更低。
研究设计与样本
- 采用本院机构数据库临床记录进行的巢式病例对照研究,纳入2010至2019年因新发膝痛就诊于门诊的患者。
- 病例组为2018至2019年行初次全膝关节置换术者,对照组为未行全膝关节置换术者,按出生日期±2年、性别、日历时间(首次门诊就诊±1年)及关节炎分级1:1匹配。
- 共纳入600例患者(病例组300例,对照组300例)。
主要发现
- 与未使用者相比,随访期间任何β受体阻滞剂使用与接受全膝关节置换术的可能性降低相关(调整OR 0.51;95%CI 0.34-0.77)。
- 选择性β1受体阻滞剂调整OR 0.69(95%CI 0.36-1.31),非选择性β1受体阻滞剂调整OR 0.42(95%CI 0.24-0.70)。
- 近期任何使用调整OR 0.65(95%CI 0.51-0.99),PDC<0.25调整OR 0.62(95%CI 0.21-1.85),PDC≥0.25至<0.75调整OR 0.32(95%CI 0.09-1.22),PDC≥0.75调整OR 0.55(95%CI 0.34-0.88)。
- 累积效应方面,使用<1年调整OR 0.41(95%CI 0.20-0.85),≥1至<5年调整OR 0.52(95%CI 0.21-1.33),≥5年调整OR 0.36(95%CI 0.22-0.60)。
关键数值与推荐
- β受体阻滞剂依从性以覆盖天数比例(PDC)衡量,分为<0.25、≥0.25至<0.75、≥0.75三档。
- 累积效应以β受体阻滞剂治疗总年数衡量,分为<1年、≥1至<5年、≥5年三档。
- 采用二分类逻辑回归分析调整潜在混杂因素,评估β受体阻滞剂摄入与全膝关节置换术风险的关系。
临床怎么用
- 原文未据此给出推荐。
局限性
- 证据等级为预后Level III。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Research has indicated that β-blockers may downregulate various inflammatory mediators that are involved in osteoarthritis (OA). The objective of this study was to analyze the likelihood of total knee arthroplasty (TKA) among patients with OA who were being treated with β-blockers. METHODS: A nested case-control study was conducted with use of clinical records from our institutional database. We included patients who attended our outpatient clinic with a history of new-onset knee pain between 2010 and 2019. The case group included individuals who had undergone primary TKA between 2018 and 2019, whereas the control group included subjects who had not undergone TKA. Controls were matched by date of birth ±2 years, sex, calendar time (first outpatient visit ±1 year), and the grade of arthritis; the control-to-case ratio was 1:1. Adherence to β-blocker use was measured with use of the proportion of days covered (PDC) (i.e.,<0.25, ≥0.25 to <0.75, ≥0.75), and the cumulative effect was measured on the basis of the total number of years of treatment with β-blockers. A binary logistic regression analysis adjusted to potential confounders was carried out to assess the risk of TKA associated with the intake of β-blockers. RESULTS: A total of 600 patients were included (300 in the case group and 300 in the control group). Compared with non-users, any use of β-blockers during the follow-up period was associated with a reduction in the likelihood of undergoing TKA (adjusted odds ratio [OR], 0.51; 95% confidence interval [CI], 0.34-0.77). The adjusted ORs for the use of selective β1-blockers and nonselective β1-blockers were 0.69 (95% CI, 0.36 to 1.31) and 0.42 (95% CI, 0.24 to 0.70), respectively. The adjusted ORs for any recent use, PDC of <0.25, PDC of ≥0.25 to <0.75, and PDC of ≥0.75 were 0.65 (95% CI, 0.51 to 0.99), 0.62 (95% CI, 0.21 to 1.85), 0.32 (95% CI, 0.09 to 1.22), and 0.55 (95% CI, 0.34 to 0.88), respectively. Regarding the cumulative effect of β-blockers, the adjusted ORs for the use for <1 year, ≥1 to <5 years, and ≥5 years were 0.41 (95% CI, 0.20 to 0.85), 0.52 (95% CI, 0.21 to 1.33), and 0.36 (95% CI, 0.22 to 0.60), respectively. CONCLUSIONS: The use of nonselective β-blockers was associated with a lower likelihood of undergoing TKA. Patients treated for prolonged periods were at a lower likelihood for undergoing TKA. LEVEL OF EVIDENCE: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.
引用
- Tamimi I, García-Meléndez G, Vieitez-Riestra I, et al. The Use of β-Blockers and the Risk of Undergoing a Knee Arthroplasty: A Nested Case-Control Study. J Bone Joint Surg Am. 2023. PMID: 37669477. doi:10.2106/JBJS.22.01189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。